Viewed as a proof of principle model for therapeutic development, our findings support an approach that would inhibit MDM2 E3 activity without preventing MDM2 p53 binding as a promising avenue for development of compounds to activate p53 in tumors with reduced on target toxicities lasix side effects on kidneys